Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With our second launch in less than 18 months, I'm proud that our team is making that vision in reality and in the process is helping a growing number of people suffering from dermatologic conditions |
| We're really happy about the response there and this regimen fits nicely with the current clinical practice, and these data have really resonated with dermatologists |
| It's really exciting to see where we have a high proportion of patients responding early and then seeing an increased benefit over time with long-term treatment |
| [Technical Difficulty] 165,000 prescriptions and over 10,700 unique prescribers to launch to-date as our product delivers positive clinical experience for HCPs and their patients |
| We also remain confident about concluding an out-licensing deal in Japan to bring in additional non-dilutive capital, which would further extend runway and largely address the capital requirement covenant with SLR |
| The solid growth in prescriptions, coupled with continued gross-to-net improvements drove strong revenue growth in Q4, both versus Q3 and year-over-year with fourth quarter net revenue of $13.5 million |
| I'm extremely proud of the team's performance in delivering on the promise of topical roflumilast in the dermatology community and hitting all our timelines with regard to our regulatory milestones |
| We also continue to execute against our clinical and regulatory milestones with a steady flow of successes this past quarter |
| So you'll see that probably tick up for psoriasis and SebDerm, but we're confident as the year progresses that gross to net will continue to improve toward the end of 2024, and I believe in our script we mentioned our target is in the 50s |
| We also released very exciting interim long-term data from our open-label study in AD that demonstrated efficacy continues to improve with long-term use out to 52 weeks, along with favorable long-term safety and dependable disease control |
| We've seen robust, consistent and predictable efficacy across all targeted indications, including psoriasis, SebDerm and atopic dermatitis in each of their respective pivotal trials |
| And in October, we completed a secondary offering that raised $102 million, putting us in a strong financial position to continue investing in the ongoing launches in plaque psoriasis and SebDerm as well as the potential atopic dermatitis launched later this year, while continuing to develop -- the development of our pipeline |
| A major reason why we're so excited for this year is that we are in the midst of a very significant expansion of the opportunity for topical roflumilast, which we expect will translate into a substantial acceleration of our revenue trajectory |
| Building on the strength of label and product profile, we are confident that we have the ingredients in place for successful launch of ZORYVE foam in SebDerm |
| We have the right commercial team in place for success, and we have an excellent plan to execute against these opportunities |
| Todd Edwards Thank you, Frank, and I'm very enthusiastic about our growing commercial portfolio, recent progress, and a tremendous opportunity I see ahead |
| The ZORYVE psoriasis launch is accelerating, and our execution strategies are showing signals that we are able to push the launch trajectory in psoriasis |
| These efforts also lay a solid foundation for sustained growth in SebDerm and potential further growth in new indications upon approval |
| We continue to work with the downstream health plans, leading them on board, and this accelerated coverage, which translate into a more rapid improvement in gross-to-net compared to what we saw with the cream launch [Technical Difficulty] derm products |
| We're excited about the roflumilast cream clinical profile for AD and the significant opportunity in this large and growing market |
| We are starting to see a preference for ZORYVE relative to the non-steroidal competitor as evidenced by our steady gains in market share and eight in 10 ZORYVE riders are increasing their utilization of ZORYVE |
| The new pediatric label expansion down to six years of age, incrementally expands our opportunity for growth and further strengthens ZORYVE's safety and tolerability profile |
| The uniqueness of the vehicle and critical efficacy needs for this patient type of rapid response at itch and erythema, which then helps to reduce the number of treatments in the regimen and potentially leads to improved compliance |
| Dynamics here at AD are favorable towards rapid adoption and share some of the positive tailwinds as SebDerm |
| After spending time with dermatologists, MPs, and PAs currently using ZORYVE cream, the feedback I received about the product is exceptional |
| With the product profile offering rapid dramatic disease clearance and significant reduction in itch with a simple single treatment, HCPs and patients are very enthusiastic about the availability of ZORYVE foam |
| And relative to our ZORYVE direct program, and I think this is a big strategic advantage for us, is that the program's identical |
| The ability to be used anywhere, once daily dosing, compelling efficacy data, favorable tolerability profile, safety, and appropriateness for any psoriasis patients |
| This was driven by substantial growth -- gross-to-net, excuse me, percentage improvement down in the mid-60s and the team's success in pulling through covered prescriptions |
| And, yeah, as mentioned, we're very pleased with the uptake of ZORYVE foam |
| Statement |
|---|
| R&D expenses for full year were $111 million, which is down $70 million, approximately due to the one-time $30 million fee associated with the Ducentis acquisition in 2022, winding down of our major roflumilast Phase III studies and lower pre-commercial production |
| And that translates into a level of frustration for the dermatologist that was kind of pent up prior to this |
| But I just caution that a linear progression based on the rate trend is probably overly optimistic |
| We don't want to be in a position of underinvesting and harming the trajectory for the ongoing launches in psoriasis and SebDerm or future launches if approved |
| R&D expenses for the fourth quarter were $23.8 million, which is down significantly from Q4 2022 due to continued decrease of development costs on topical roflumilast programs |
| Launching drugs properly require substantial investments in staff and promotional investment and having multiple launches in a short period of time really magnifies these resource demands |
| You know, seborrheic dermatitis patients can be a challenging patient type in the dermatology practice just because you've had them in your practice for, you know, 10, 15 years sometimes |
| There has not been any new innovation within this space in two decades, and the enthusiasm by providers around this product |
| We expect full year 2024 R&D expense to decline meaningfully versus full year 2023 as we continue completing the few remaining Phase III studies continuing with regulatory filings, reduce our prelaunch production costs, and maintain our medical fares activity to support the launches |
| ZORYVE's pricing falls below the CMS specialty threshold tier, unlike other branded topicals |
| So, the SebDerm prescriptions for ZORYVE foam have gotten vertical very early in the launch and have reached levels that ZORYVE cream and Botama took significant longer to reach |
Please consider a small donation if you think this website provides you with relevant information